<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848753</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-042-III-ESCC</org_study_id>
    <nct_id>NCT04848753</nct_id>
  </id_info>
  <brief_title>Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, multi-center, double-blinded, Phase III study to&#xD;
      determine the efficacy and safety of patients with locally advanced squamous cell carcinoma&#xD;
      of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant&#xD;
      chemotherapy versus placebo combined with neoadjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 12, 2021</start_date>
  <completion_date type="Anticipated">May 12, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 12, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare IRC-assessed events-free survival (EFS) in 2 arms</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pathologically complete remission (pCR) rate</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months</time_frame>
    <description>To compare the percentage of patients who achieved pCR in the 2 arms, pCR rate was defined as the percentage of subjects who achieved a complete pathological response (PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed EFS according to RECIST v1.1</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months</time_frame>
    <description>To compare Investigator-assessed events-free survival (EFS) in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months</time_frame>
    <description>To compare Overall survival in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year OS rate</measure>
    <time_frame>from randomization to death from any cause at 1 year</time_frame>
    <description>To compare 1-year OS rates in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3- year OS rate</measure>
    <time_frame>from randomization to death from any cause at 3 year</time_frame>
    <description>To compare 3-year OS rates in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5- year OS rate</measure>
    <time_frame>from randomization to death from any cause at 5 year</time_frame>
    <description>To compare 5-year OS rates in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Toripalimab combined with cisplatin and paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo combined with cisplatin and paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Toripalimab combined with cisplatin and paclitaxel</intervention_name>
    <description>Specified doses on specified days.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo combined with cisplatin and paclitaxel</intervention_name>
    <description>Specified doses on specified days.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must fulfill all of the following inclusion criteria to be eligible for enrollment&#xD;
        in this study:&#xD;
&#xD;
          1. Histologically confirmed locally advanced (T1N1-3M0 or T2-3N0-3M0) squamous cell&#xD;
             carcinoma of the thoracic esophagus (per the 8th Edition of UICC-TNM Classification);&#xD;
&#xD;
          2. No suspicious cervical lymph node metastasis on cervical contrast-enhanced CT; no&#xD;
             systemic metastasis from radiological examination;&#xD;
&#xD;
          3. Expected to be achievable to conduct R0 resection.&#xD;
&#xD;
        Patients must not enter this study if any of the following exclusion criteria is fulfilled:&#xD;
&#xD;
          1. Having malignant tumors other than esophageal carcinoma within 5 years prior to&#xD;
             randomization;&#xD;
&#xD;
          2. Combined with other inoperable condition;&#xD;
&#xD;
          3. Previous serious allergy to chemotherapeutic agents (paclitaxel or cisplatin) or any&#xD;
             monoclonal antibody;&#xD;
&#xD;
          4. Combined with other conditions unsuitable for participation in this study as judged by&#xD;
             investigators.&#xD;
&#xD;
        Other protocol defined Inclusion/exclusion criteria could apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hongtao Han</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan Cancer Hospital &amp; Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yan Zheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaojun Wang</last_name>
    <phone>021-50796193</phone>
    <email>xiaojun_wang@junshipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Firest Affiliated Hospital of bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>jiachi ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>zhendong chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangmen central Hospital</name>
      <address>
        <city>Jiangmen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhichao Lin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anyang Cancer Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fuyou Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of xinxiang Medical University</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>yinghua ji</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yang Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Xinjiang Medical University</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yong Tang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lin Shen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital of Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guangyu An</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fan Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>shaohua Ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The General Hospital of People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guoqiang Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heping Hospital Affiliated to changzhi Medical College</name>
      <address>
        <city>Changzhi</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Changhong Lian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital &amp; Institute</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yongtao Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shuoyan Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianhua Fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>3201 Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yong Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qixun Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jian Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>harbin medical university Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanqiao Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hu Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huai'an First People's Hospital</name>
      <address>
        <city>Huai'an</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianqiang Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of jining Medical University</name>
      <address>
        <city>Jining</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junye Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of He'nan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Yao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bentong Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guochun Cao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhuang Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lijie Tan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shantou University Cancer Hospital</name>
      <address>
        <city>Shantou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuping Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning cancer hospital&amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongxu Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Caigang Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first Hospital of china Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiujuan Qu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hebei General Hospital</name>
      <address>
        <city>Shijia Zhuang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaopeng Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Peng Tang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fei Xiong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qing Geng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ke Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Feng Ye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongbing Duan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinyang central Hospital</name>
      <address>
        <city>Xinyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liangfeng Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuanhu Yao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yantai yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ping Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Zheng</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

